1	1	_	_	CD	_	_	_	_	_
2	.	_	_	.	_	_	_	_	_


1	Introduction	_	_	NN	_	_	_	_	_


1	Early	_	_	JJ	_	_	_	_	_
2	diagnosis	_	_	NN	_	_	_	_	_
3	and	_	_	CC	_	_	_	_	_
4	treatment	_	_	NN	_	_	_	_	_
5	of	_	_	IN	_	_	_	_	_
6	human	_	_	JJ	_	_	_	_	_
7	malaria	_	_	NN	_	_	_	_	_
8	reduces	_	_	VBZ	_	_	_	_	_
9	disease	_	_	NN	_	_	_	_	_
10	,	_	_	,	_	_	_	_	_
11	prevents	_	_	VBZ	_	_	_	_	_
12	deaths	_	_	NNS	_	_	_	_	_
13	,	_	_	,	_	_	_	_	_
14	and	_	_	CC	_	_	_	_	_
15	contributes	_	_	VBZ	_	_	_	_	_
16	to	_	_	TO	_	_	_	_	_
17	reduced	_	_	VBN	_	_	_	_	_
18	transmission	_	_	NN	_	_	_	_	_
19	.	_	_	.	_	_	_	_	_


1	Detection	_	_	NN	_	_	_	_	_
2	of	_	_	IN	_	_	_	_	_
3	antibody	_	_	NN	_	_	_	_	_
4	response	_	_	NN	_	_	_	_	_
5	against	_	_	IN	_	_	_	_	_
6	malaria	_	_	NN	_	_	_	_	_
7	antigens	_	_	NNS	_	_	_	_	_
8	is	_	_	VBZ	_	_	_	_	_
9	often	_	_	RB	_	_	_	_	_
10	done	_	_	VBN	_	_	_	_	_
11	through	_	_	IN	_	_	_	_	_
12	Enzyme-Linked	_	_	JJ	_	_	_	_	_
13	Immunosorbent	_	_	NN	_	_	_	_	_
14	Assay	_	_	NN	_	_	_	_	_
15	(	_	_	-LRB-	_	_	_	_	_
16	ELISA	_	_	NNP	_	_	_	_	_
17	)	_	_	-RRB-	_	_	_	_	_
18	;	_	_	:	_	_	_	_	_
19	many	_	_	JJ	_	_	_	_	_
20	of	_	_	IN	_	_	_	_	_
21	these	_	_	DT	_	_	_	_	_
22	diagnostic	_	_	JJ	_	_	_	_	_
23	assays	_	_	NNS	_	_	_	_	_
24	are	_	_	VBP	_	_	_	_	_
25	designed	_	_	VBN	_	_	_	_	_
26	with	_	_	IN	_	_	_	_	_
27	a	_	_	DT	_	_	_	_	_
28	single	_	_	JJ	_	_	_	_	_
29	antigen	_	_	NN	_	_	_	_	_
30	or	_	_	CC	_	_	_	_	_
31	with	_	_	IN	_	_	_	_	_
32	recombinant	_	_	JJ	_	_	_	_	_
33	antigens	_	_	NNS	_	_	_	_	_
34	of	_	_	IN	_	_	_	_	_
35	different	_	_	JJ	_	_	_	_	_
36	stages	_	_	NNS	_	_	_	_	_
37	of	_	_	IN	_	_	_	_	_
38	the	_	_	DT	_	_	_	_	_
39	parasites	_	_	NNS	_	_	_	_	_
40	(	_	_	-LRB-	_	_	_	_	_
41	tissue	_	_	NN	_	_	_	_	_
42	infection	_	_	NN	_	_	_	_	_
43	or	_	_	CC	_	_	_	_	_
44	blood	_	_	NN	_	_	_	_	_
45	)	_	_	-RRB-	_	_	_	_	_
46	,	_	_	,	_	_	_	_	_
47	where	_	_	WRB	_	_	_	_	_
48	merozoite	_	_	NN	_	_	_	_	_
49	surface	_	_	NN	_	_	_	_	_
50	proteins	_	_	NNS	_	_	_	_	_
51	can	_	_	MD	_	_	_	_	_
52	be	_	_	VB	_	_	_	_	_
53	detected	_	_	VBN	_	_	_	_	_
54	,	_	_	,	_	_	_	_	_
55	and	_	_	CC	_	_	_	_	_
56	have	_	_	VBP	_	_	_	_	_
57	demonstrated	_	_	VBN	_	_	_	_	_
58	good	_	_	JJ	_	_	_	_	_
59	sensitivity	_	_	NN	_	_	_	_	_
60	and	_	_	CC	_	_	_	_	_
61	specificity	_	_	NN	_	_	_	_	_
62	.	_	_	.	_	_	_	_	_


1	However	_	_	RB	_	_	_	_	_
2	,	_	_	,	_	_	_	_	_
3	many	_	_	JJ	_	_	_	_	_
4	individuals	_	_	NNS	_	_	_	_	_
5	cannot	_	_	MD	_	_	_	_	_
6	be	_	_	VB	_	_	_	_	_
7	easily	_	_	RB	_	_	_	_	_
8	diagnosed	_	_	VBN	_	_	_	_	_
9	due	_	_	JJ	_	_	_	_	_
10	to	_	_	TO	_	_	_	_	_
11	the	_	_	DT	_	_	_	_	_
12	low	_	_	JJ	_	_	_	_	_
13	levels	_	_	NNS	_	_	_	_	_
14	of	_	_	IN	_	_	_	_	_
15	antibodies	_	_	NNS	_	_	_	_	_
16	present	_	_	JJ	_	_	_	_	_
17	in	_	_	IN	_	_	_	_	_
18	their	_	_	PRP$	_	_	_	_	_
19	blood	_	_	NN	_	_	_	_	_
20	.	_	_	.	_	_	_	_	_


1	In	_	_	IN	_	_	_	_	_
2	this	_	_	DT	_	_	_	_	_
3	context	_	_	NN	_	_	_	_	_
4	,	_	_	,	_	_	_	_	_
5	the	_	_	DT	_	_	_	_	_
6	use	_	_	NN	_	_	_	_	_
7	of	_	_	IN	_	_	_	_	_
8	ELISA	_	_	NNP	_	_	_	_	_
9	as	_	_	IN	_	_	_	_	_
10	a	_	_	DT	_	_	_	_	_
11	tool	_	_	NN	_	_	_	_	_
12	for	_	_	IN	_	_	_	_	_
13	laboratory	_	_	NN	_	_	_	_	_
14	diagnosis	_	_	NN	_	_	_	_	_
15	of	_	_	IN	_	_	_	_	_
16	malaria	_	_	NN	_	_	_	_	_
17	has	_	_	VBZ	_	_	_	_	_
18	some	_	_	DT	_	_	_	_	_
19	limitations	_	_	NNS	_	_	_	_	_
20	,	_	_	,	_	_	_	_	_
21	namely	_	_	RB	_	_	_	_	_
22	:	_	_	:	_	_	_	_	_
23	(	_	_	-LRB-	_	_	_	_	_
24	i	_	_	CD	_	_	_	_	_
25	)	_	_	-RRB-	_	_	_	_	_
26	low	_	_	JJ	_	_	_	_	_
27	antibody	_	_	NN	_	_	_	_	_
28	titres	_	_	NNS	_	_	_	_	_
29	presented	_	_	VBN	_	_	_	_	_
30	by	_	_	IN	_	_	_	_	_
31	individuals	_	_	NNS	_	_	_	_	_
32	in	_	_	IN	_	_	_	_	_
33	the	_	_	DT	_	_	_	_	_
34	acute	_	_	JJ	_	_	_	_	_
35	phase	_	_	NN	_	_	_	_	_
36	of	_	_	IN	_	_	_	_	_
37	infection	_	_	NN	_	_	_	_	_
38	;	_	_	:	_	_	_	_	_
39	(	_	_	-LRB-	_	_	_	_	_
40	ii	_	_	NN	_	_	_	_	_
41	)	_	_	-RRB-	_	_	_	_	_
42	many	_	_	JJ	_	_	_	_	_
43	Plasmodium	_	_	NN	_	_	_	_	_
44	sp	_	_	NN	_	_	_	_	_
45	.	_	_	.	_	_	_	_	_
46	are	_	_	VBP	_	_	_	_	_
47	involved	_	_	VBN	_	_	_	_	_
48	in	_	_	IN	_	_	_	_	_
49	human	_	_	JJ	_	_	_	_	_
50	malaria	_	_	NN	_	_	_	_	_
51	;	_	_	:	_	_	_	_	_
52	(	_	_	-LRB-	_	_	_	_	_
53	iii	_	_	NN	_	_	_	_	_
54	)	_	_	-RRB-	_	_	_	_	_
55	different	_	_	JJ	_	_	_	_	_
56	evolutionary	_	_	JJ	_	_	_	_	_
57	forms	_	_	NNS	_	_	_	_	_
58	of	_	_	IN	_	_	_	_	_
59	Plasmodium	_	_	NN	_	_	_	_	_
60	spp.	_	_	NNS	_	_	_	_	_
61	during	_	_	IN	_	_	_	_	_
62	infection	_	_	NN	_	_	_	_	_
63	and	_	_	CC	_	_	_	_	_
64	life	_	_	NN	_	_	_	_	_
65	cycle	_	_	NN	_	_	_	_	_
66	;	_	_	:	_	_	_	_	_
67	and	_	_	CC	_	_	_	_	_
68	(	_	_	-LRB-	_	_	_	_	_
69	iv	_	_	NN	_	_	_	_	_
70	)	_	_	-RRB-	_	_	_	_	_
71	different	_	_	JJ	_	_	_	_	_
72	resistance	_	_	NN	_	_	_	_	_
73	and	_	_	CC	_	_	_	_	_
74	susceptibility	_	_	NN	_	_	_	_	_
75	profiles	_	_	NNS	_	_	_	_	_
76	during	_	_	IN	_	_	_	_	_
77	infection	_	_	NN	_	_	_	_	_
78	,	_	_	,	_	_	_	_	_
79	and	_	_	CC	_	_	_	_	_
80	consequently	_	_	RB	_	_	_	_	_
81	in	_	_	IN	_	_	_	_	_
82	the	_	_	DT	_	_	_	_	_
83	immunity	_	_	NN	_	_	_	_	_
84	profile	_	_	NN	_	_	_	_	_
85	against	_	_	IN	_	_	_	_	_
86	malaria	_	_	NN	_	_	_	_	_
87	parasites	_	_	NNS	_	_	_	_	_
88	.	_	_	.	_	_	_	_	_


1	Associations	_	_	NNS	_	_	_	_	_
2	among	_	_	IN	_	_	_	_	_
3	antibodies	_	_	NNS	_	_	_	_	_
4	against	_	_	IN	_	_	_	_	_
5	parasite	_	_	NN	_	_	_	_	_
6	antigens	_	_	NNS	_	_	_	_	_
7	and	_	_	CC	_	_	_	_	_
8	malaria	_	_	NN	_	_	_	_	_
9	risk	_	_	NN	_	_	_	_	_
10	areas	_	_	NNS	_	_	_	_	_
11	are	_	_	VBP	_	_	_	_	_
12	not	_	_	RB	_	_	_	_	_
13	always	_	_	RB	_	_	_	_	_
14	consistent	_	_	JJ	_	_	_	_	_
15	;	_	_	:	_	_	_	_	_
16	some	_	_	DT	_	_	_	_	_
17	may	_	_	MD	_	_	_	_	_
18	depend	_	_	VB	_	_	_	_	_
19	on	_	_	IN	_	_	_	_	_
20	parasite	_	_	NN	_	_	_	_	_
21	antigens	_	_	NNS	_	_	_	_	_
22	and	_	_	CC	_	_	_	_	_
23	other	_	_	JJ	_	_	_	_	_
24	considerations	_	_	NNS	_	_	_	_	_
25	may	_	_	MD	_	_	_	_	_
26	be	_	_	VB	_	_	_	_	_
27	due	_	_	JJ	_	_	_	_	_
28	to	_	_	TO	_	_	_	_	_
29	the	_	_	DT	_	_	_	_	_
30	endemic	_	_	JJ	_	_	_	_	_
31	areas	_	_	NNS	_	_	_	_	_
32	of	_	_	IN	_	_	_	_	_
33	malaria	_	_	NN	_	_	_	_	_
34	.	_	_	.	_	_	_	_	_


1	It	_	_	PRP	_	_	_	_	_
2	should	_	_	MD	_	_	_	_	_
3	be	_	_	VB	_	_	_	_	_
4	considered	_	_	VBN	_	_	_	_	_
5	that	_	_	IN	_	_	_	_	_
6	single	_	_	JJ	_	_	_	_	_
7	responses	_	_	NNS	_	_	_	_	_
8	of	_	_	IN	_	_	_	_	_
9	antibodies	_	_	NNS	_	_	_	_	_
10	against	_	_	IN	_	_	_	_	_
11	antigens	_	_	NNS	_	_	_	_	_
12	might	_	_	MD	_	_	_	_	_
13	be	_	_	VB	_	_	_	_	_
14	inadequate	_	_	JJ	_	_	_	_	_
15	to	_	_	TO	_	_	_	_	_
16	for	_	_	IN	_	_	_	_	_
17	use	_	_	NN	_	_	_	_	_
18	as	_	_	IN	_	_	_	_	_
19	biomarkers	_	_	NNS	_	_	_	_	_
20	and	_	_	CC	_	_	_	_	_
21	indicators	_	_	NNS	_	_	_	_	_
22	of	_	_	IN	_	_	_	_	_
23	malaria	_	_	NN	_	_	_	_	_
24	transmission	_	_	NN	_	_	_	_	_
25	intensity	_	_	NN	_	_	_	_	_
26	.	_	_	.	_	_	_	_	_


1	Other	_	_	JJ	_	_	_	_	_
2	authors	_	_	NNS	_	_	_	_	_
3	have	_	_	VBP	_	_	_	_	_
4	shown	_	_	VBN	_	_	_	_	_
5	that	_	_	IN	_	_	_	_	_
6	new	_	_	JJ	_	_	_	_	_
7	serological	_	_	JJ	_	_	_	_	_
8	biomarkers	_	_	NNS	_	_	_	_	_
9	can	_	_	MD	_	_	_	_	_
10	more	_	_	RBR	_	_	_	_	_
11	accurately	_	_	RB	_	_	_	_	_
12	estimate	_	_	VB	_	_	_	_	_
13	the	_	_	DT	_	_	_	_	_
14	recent	_	_	JJ	_	_	_	_	_
15	exposure	_	_	NN	_	_	_	_	_
16	to	_	_	TO	_	_	_	_	_
17	P.	_	_	NNP	_	_	_	_	_
18	falciparum	_	_	NN	_	_	_	_	_
19	not	_	_	RB	_	_	_	_	_
20	only	_	_	RB	_	_	_	_	_
21	of	_	_	IN	_	_	_	_	_
22	a	_	_	DT	_	_	_	_	_
23	community	_	_	NN	_	_	_	_	_
24	,	_	_	,	_	_	_	_	_
25	but	_	_	CC	_	_	_	_	_
26	also	_	_	RB	_	_	_	_	_
27	for	_	_	IN	_	_	_	_	_
28	several	_	_	JJ	_	_	_	_	_
29	communities	_	_	NNS	_	_	_	_	_
30	.	_	_	.	_	_	_	_	_


1	In	_	_	IN	_	_	_	_	_
2	2015	_	_	CD	_	_	_	_	_
3	,	_	_	,	_	_	_	_	_
4	approximately	_	_	RB	_	_	_	_	_
5	3.2	_	_	CD	_	_	_	_	_
6	billion	_	_	CD	_	_	_	_	_
7	people	_	_	NNS	_	_	_	_	_
8	—	_	_	:	_	_	_	_	_
9	nearly	_	_	RB	_	_	_	_	_
10	half	_	_	NN	_	_	_	_	_
11	of	_	_	IN	_	_	_	_	_
12	the	_	_	DT	_	_	_	_	_
13	world	_	_	NN	_	_	_	_	_
14	’s	_	_	POS	_	_	_	_	_
15	population	_	_	NN	_	_	_	_	_
16	—	_	_	:	_	_	_	_	_
17	were	_	_	VBD	_	_	_	_	_
18	at	_	_	IN	_	_	_	_	_
19	risk	_	_	NN	_	_	_	_	_
20	of	_	_	IN	_	_	_	_	_
21	malaria	_	_	NN	_	_	_	_	_
22	,	_	_	,	_	_	_	_	_
23	mainly	_	_	RB	_	_	_	_	_
24	by	_	_	IN	_	_	_	_	_
25	P.	_	_	NNP	_	_	_	_	_
26	falciparum	_	_	NN	_	_	_	_	_
27	.	_	_	.	_	_	_	_	_


1	After	_	_	IN	_	_	_	_	_
2	several	_	_	JJ	_	_	_	_	_
3	decades	_	_	NNS	_	_	_	_	_
4	of	_	_	IN	_	_	_	_	_
5	disease	_	_	NN	_	_	_	_	_
6	control	_	_	NN	_	_	_	_	_
7	campaigns	_	_	NNS	_	_	_	_	_
8	,	_	_	,	_	_	_	_	_
9	malaria	_	_	NN	_	_	_	_	_
10	persists	_	_	VBZ	_	_	_	_	_
11	as	_	_	IN	_	_	_	_	_
12	one	_	_	CD	_	_	_	_	_
13	of	_	_	IN	_	_	_	_	_
14	the	_	_	DT	_	_	_	_	_
15	most	_	_	RBS	_	_	_	_	_
16	serious	_	_	JJ	_	_	_	_	_
17	public	_	_	JJ	_	_	_	_	_
18	health	_	_	NN	_	_	_	_	_
19	problems	_	_	NNS	_	_	_	_	_
20	,	_	_	,	_	_	_	_	_
21	not	_	_	RB	_	_	_	_	_
22	only	_	_	RB	_	_	_	_	_
23	in	_	_	IN	_	_	_	_	_
24	endemic	_	_	JJ	_	_	_	_	_
25	countries	_	_	NNS	_	_	_	_	_
26	,	_	_	,	_	_	_	_	_
27	but	_	_	CC	_	_	_	_	_
28	also	_	_	RB	_	_	_	_	_
29	in	_	_	IN	_	_	_	_	_
30	non-endemic	_	_	JJ	_	_	_	_	_
31	regions	_	_	NNS	_	_	_	_	_
32	,	_	_	,	_	_	_	_	_
33	where	_	_	WRB	_	_	_	_	_
34	the	_	_	DT	_	_	_	_	_
35	number	_	_	NN	_	_	_	_	_
36	of	_	_	IN	_	_	_	_	_
37	cases	_	_	NNS	_	_	_	_	_
38	of	_	_	IN	_	_	_	_	_
39	imported	_	_	VBN	_	_	_	_	_
40	malaria	_	_	NN	_	_	_	_	_
41	via	_	_	IN	_	_	_	_	_
42	tourists	_	_	NNS	_	_	_	_	_
43	and	_	_	CC	_	_	_	_	_
44	immigrants	_	_	NNS	_	_	_	_	_
45	is	_	_	VBZ	_	_	_	_	_
46	on	_	_	IN	_	_	_	_	_
47	the	_	_	DT	_	_	_	_	_
48	rise	_	_	NN	_	_	_	_	_
49	.	_	_	.	_	_	_	_	_


1	P.	_	_	NNP	_	_	_	_	_
2	falciparum	_	_	NNP	_	_	_	_	_


1	is	_	_	VBZ	_	_	_	_	_
2	one	_	_	CD	_	_	_	_	_
3	the	_	_	DT	_	_	_	_	_
4	most	_	_	RBS	_	_	_	_	_
5	lethal	_	_	JJ	_	_	_	_	_
6	species	_	_	NNS	_	_	_	_	_
7	of	_	_	IN	_	_	_	_	_
8	the	_	_	DT	_	_	_	_	_
9	malaria	_	_	NN	_	_	_	_	_
10	parasites	_	_	NNS	_	_	_	_	_
11	that	_	_	WDT	_	_	_	_	_
12	infect	_	_	VBP	_	_	_	_	_
13	humans	_	_	NNS	_	_	_	_	_
14	,	_	_	,	_	_	_	_	_
15	and	_	_	CC	_	_	_	_	_
16	is	_	_	VBZ	_	_	_	_	_
17	responsible	_	_	JJ	_	_	_	_	_
18	for	_	_	IN	_	_	_	_	_
19	the	_	_	DT	_	_	_	_	_
20	highest	_	_	JJS	_	_	_	_	_
21	number	_	_	NN	_	_	_	_	_
22	of	_	_	IN	_	_	_	_	_
23	serious	_	_	JJ	_	_	_	_	_
24	pathologies	_	_	NNS	_	_	_	_	_
25	associated	_	_	VBN	_	_	_	_	_
26	with	_	_	IN	_	_	_	_	_
27	the	_	_	DT	_	_	_	_	_
28	disease	_	_	NN	_	_	_	_	_
29	.	_	_	.	_	_	_	_	_


1	In	_	_	IN	_	_	_	_	_
2	this	_	_	DT	_	_	_	_	_
3	work	_	_	NN	_	_	_	_	_
4	,	_	_	,	_	_	_	_	_
5	we	_	_	PRP	_	_	_	_	_
6	performed	_	_	VBD	_	_	_	_	_
7	a	_	_	DT	_	_	_	_	_
8	comparative	_	_	JJ	_	_	_	_	_
9	analysis	_	_	NN	_	_	_	_	_
10	of	_	_	IN	_	_	_	_	_
11	the	_	_	DT	_	_	_	_	_
12	serological	_	_	JJ	_	_	_	_	_
13	reactivity	_	_	NN	_	_	_	_	_
14	of	_	_	IN	_	_	_	_	_
15	total	_	_	JJ	_	_	_	_	_
16	antimalarial	_	_	JJ	_	_	_	_	_
17	antibodies	_	_	NNS	_	_	_	_	_
18	obtained	_	_	VBN	_	_	_	_	_
19	by	_	_	IN	_	_	_	_	_
20	a	_	_	DT	_	_	_	_	_
21	commercial	_	_	JJ	_	_	_	_	_
22	ELISA	_	_	NNP	_	_	_	_	_
23	using	_	_	VBG	_	_	_	_	_
24	recombinant	_	_	JJ	_	_	_	_	_
25	antigens	_	_	NNS	_	_	_	_	_
26	from	_	_	IN	_	_	_	_	_
27	Plasmodium	_	_	NNP	_	_	_	_	_
28	sp	_	_	NNP	_	_	_	_	_
29	.	_	_	.	_	_	_	_	_
30	,	_	_	,	_	_	_	_	_
31	compared	_	_	VBN	_	_	_	_	_
32	to	_	_	TO	_	_	_	_	_
33	an	_	_	DT	_	_	_	_	_
34	in-house	_	_	JJ	_	_	_	_	_
35	ELISA	_	_	NNP	_	_	_	_	_
36	,	_	_	,	_	_	_	_	_
37	using	_	_	VBG	_	_	_	_	_
38	crude	_	_	JJ	_	_	_	_	_
39	extract	_	_	NN	_	_	_	_	_
40	of	_	_	IN	_	_	_	_	_
41	P.	_	_	NN	_	_	_	_	_
42	falciparum	_	_	NN	_	_	_	_	_
43	3D7	_	_	CD	_	_	_	_	_
44	.	_	_	.	_	_	_	_	_


1	Thus	_	_	RB	_	_	_	_	_
2	,	_	_	,	_	_	_	_	_
3	we	_	_	PRP	_	_	_	_	_
4	showed	_	_	VBD	_	_	_	_	_
5	that	_	_	IN	_	_	_	_	_
6	several	_	_	JJ	_	_	_	_	_
7	other	_	_	JJ	_	_	_	_	_
8	P.	_	_	NN	_	_	_	_	_
9	falciparum	_	_	NN	_	_	_	_	_
10	antigens	_	_	NNS	_	_	_	_	_
11	are	_	_	VBP	_	_	_	_	_
12	equally	_	_	RB	_	_	_	_	_
13	important	_	_	JJ	_	_	_	_	_
14	for	_	_	IN	_	_	_	_	_
15	the	_	_	DT	_	_	_	_	_
16	serological	_	_	JJ	_	_	_	_	_
17	diagnosis	_	_	NN	_	_	_	_	_
18	of	_	_	IN	_	_	_	_	_
19	malaria	_	_	NN	_	_	_	_	_
20	,	_	_	,	_	_	_	_	_
21	as	_	_	RB	_	_	_	_	_
22	well	_	_	RB	_	_	_	_	_
23	as	_	_	IN	_	_	_	_	_
24	some	_	_	DT	_	_	_	_	_
25	recombinant	_	_	JJ	_	_	_	_	_
26	antigens	_	_	NNS	_	_	_	_	_
27	commonly	_	_	RB	_	_	_	_	_
28	used	_	_	VBN	_	_	_	_	_
29	in	_	_	IN	_	_	_	_	_
30	commercial	_	_	JJ	_	_	_	_	_
31	ELISA	_	_	NNP	_	_	_	_	_
32	.	_	_	.	_	_	_	_	_

